Cargando…
Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
INTRODUCTION: In a pivotal study, apomorphine sublingual film (APL; KYNMOBI(®)) was an effective and generally well-tolerated on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD), approved across the dose range of 10–30 mg. Pharmacokinetics and comparative bioavailability...
Autores principales: | Agbo, Felix, Isaacson, Stuart H., Gil, Ramon, Chiu, Yu-Yuan, Brantley, Scott J., Bhargava, Parul, Navia, Bradford |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571442/ https://www.ncbi.nlm.nih.gov/pubmed/33991326 http://dx.doi.org/10.1007/s40120-021-00251-6 |
Ejemplares similares
-
Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
por: Agbo, Felix, et al.
Publicado: (2021) -
Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?
por: Hauser, Robert A., et al.
Publicado: (2023) -
A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease
por: Stocchi, Fabrizio, et al.
Publicado: (2022) -
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020) -
Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)